-
A125594-10mgAM966 is a high affinity, selective, oral LPA1 (lysophosphatidic acid receptor, IC50=17 nM) antagonist, with selectivity for this receptor over the other LPA receptors.
-
A125594-50mgAM966 is a high affinity, selective, oral LPA1 (lysophosphatidic acid receptor, IC50=17 nM) antagonist, with selectivity for this receptor over the other LPA receptors.
-
A125594-5mgAM966 is a high affinity, selective, oral LPA1 (lysophosphatidic acid receptor, IC50=17 nM) antagonist, with selectivity for this receptor over the other LPA receptors.
-
-
-
A125972-10mgAmadacycline.
-
A125972-25mgAmadacycline.
-
A125972-50mgAmadacycline.
-
A125972-5mgAmadacycline.
-
A414065-100mgInformationAmcasertib (BBI503) Amcasertib (BBI503), a first-in-class cancer stemness kinase inhibitor, is claimed to inhibit Nanog and other CSC pathways by targeting kinases with potential anticancer activity.TargetsNanogIn vitroBBI-503 is
-
A414065-10mgInformationAmcasertib (BBI503) Amcasertib (BBI503), a first-in-class cancer stemness kinase inhibitor, is claimed to inhibit Nanog and other CSC pathways by targeting kinases with potential anticancer activity.TargetsNanogIn vitroBBI-503 is
-
A414065-25mgInformationAmcasertib (BBI503) Amcasertib (BBI503), a first-in-class cancer stemness kinase inhibitor, is claimed to inhibit Nanog and other CSC pathways by targeting kinases with potential anticancer activity.TargetsNanogIn vitroBBI-503 is